PMID- 34975881
OWN - NLM
STAT- MEDLINE
DCOM- 20220208
LR  - 20220208
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 12
DP  - 2021
TI  - FcgammaR Genetic Variation and HIV-1 Vaccine Efficacy: Context And Considerations.
PG  - 788203
LID - 10.3389/fimmu.2021.788203 [doi]
LID - 788203
AB  - Receptors for the crystallisable fragment (Fc) of immunoglobulin (Ig) G, Fcgamma 
      receptors (FcgammaRs), link the humoral and cellular arms of the immune response, 
      providing a diverse armamentarium of antimicrobial effector functions. Findings 
      from HIV-1 vaccine efficacy trials highlight the need for further study of Fc-FcR 
      interactions in understanding what may constitute vaccine-induced protective 
      immunity. These include host genetic correlates identified within the low 
      affinity Fcgamma-receptor locus in three HIV-1 efficacy trials - VAX004, RV144, and 
      HVTN 505. This perspective summarizes our present knowledge of FcgammaR genetics in 
      the context of findings from HIV-1 efficacy trials, and draws on genetic 
      variation described in other contexts, such as mother-to-child HIV-1 transmission 
      and HIV-1 disease progression, to explore the potential contribution of FcgammaR 
      variability in modulating different HIV-1 vaccine efficacy outcomes. Appreciating 
      the complexity and the importance of the collective contribution of variation 
      within the FCGR gene locus is important for understanding the role of FcgammaRs in 
      protection against HIV-1 acquisition.
CI  - Copyright (c) 2021 Lassauniere and Tiemessen.
FAU - Lassauniere, Ria
AU  - Lassauniere R
AD  - Virus and Microbiological Special Diagnostics, Statens Serum Institut, 
      Copenhagen, Denmark.
FAU - Tiemessen, Caroline T
AU  - Tiemessen CT
AD  - Centre for HIV and STI's, National Institute for Communicable Diseases, 
      Johannesburg, South Africa.
AD  - Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South 
      Africa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211215
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (AIDS Vaccines)
RN  - 0 (Receptors, IgG)
SB  - IM
MH  - AIDS Vaccines/*immunology
MH  - Clinical Trials as Topic
MH  - Genetic Variation
MH  - HIV-1/*immunology
MH  - Haplotypes
MH  - Humans
MH  - Male
MH  - Receptors, IgG/*genetics
MH  - Vaccine Efficacy
PMC - PMC8714752
OTO - NOTNLM
OT  - FCGR genes
OT  - Fc gamma receptor (FcgammaR)
OT  - HIV - human immunodeficiency virus
OT  - copy number
OT  - disease progression
OT  - polymorphism
OT  - vaccine
OT  - variant
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/01/04 06:00
MHDA- 2022/02/09 06:00
PMCR- 2021/01/01
CRDT- 2022/01/03 05:38
PHST- 2021/10/01 00:00 [received]
PHST- 2021/11/29 00:00 [accepted]
PHST- 2022/01/03 05:38 [entrez]
PHST- 2022/01/04 06:00 [pubmed]
PHST- 2022/02/09 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2021.788203 [doi]
PST - epublish
SO  - Front Immunol. 2021 Dec 15;12:788203. doi: 10.3389/fimmu.2021.788203. eCollection 
      2021.